Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Y-Mabs Therapeutics Inc shares valued at $875,550 were sold by Gad Thomas on Sep 13 ’24. At $13.47 per share, Gad Thomas sold 65,000 shares. The insider’s holdings dropped to 97,681 shares worth approximately $1.16 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Gad Thomas sold 30,000 shares, netting a total of over 389,100 in proceeds. Following the sale of shares at $12.97 each, the insider now holds 67,681 shares.
Before that, Thomas Gad had added 100,000 shares to its account. In a trade valued at $1,374,000, the Officer bought Y-Mabs Therapeutics Inc shares for $13.74 each.
As published in their initiating research note from Oppenheimer on November 18, 2024, Y-Mabs Therapeutics Inc [YMAB] has been an Outperform and the price target has been revised to $23. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid August. As of June 28, 2024, Truist has initiated its “Buy” rating for YMAB. Earlier on May 10, 2023, Wedbush upgraded its rating. Their new recommendation was “an Outperform” for YMAB stock which previously was a “a Neutral”.
Analyzing YMAB Stock Performance
During the last five days, there has been a surge of approximately 12.71%. Over the course of the year, Y-Mabs Therapeutics Inc shares have jumped approximately 74.19%. Shares of the company reached a 52-week high of $20.90 on 03/01/24 and a 52-week low of $6.48 on 01/03/24. A 50-day SMA is recorded $13.54, while a 200-day SMA reached $13.69. Nevertheless, trading volume fell to 0.23 million shares from 0.23 million shares the previous day.
Support And Resistance Levels for Y-Mabs Therapeutics Inc (YMAB)
According to the 24-hour chart, there is a support level at 11.03, which, if violated, would cause prices to drop to 10.18. In the upper region, resistance lies at 12.36. The next price resistance is at 12.85. RSI (Relative Strength Index) is 43.82 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.74, which suggests the price will decrease in the coming days. Percent R is at 65.21%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
